54824-07-6

Basic information

• Product Name: 4-Phenyl-4-piperidinecarboxylic acid methyl ester
• Synonyms: 4-Phenyl-4-piperidinecarboxylic acid methyl ester
• CAS NO: 54824-07-6
• Molecular Formula: C₁₃H₁₇NO₂
• Molecular Weight: 219.28
• Mol File: 54824-07-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Phenyl-4-piperidinecarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Phenyl-4-piperidinecarboxylic acid methyl ester(54824-07-6)
• EPA Substance Registry System: 4-Phenyl-4-piperidinecarboxylic acid methyl ester(54824-07-6)

Safety Data

• Hazardous Substances Data: 54824-07-6(Hazardous Substances Data)

Upstream product

• 101-41-7 benzeneacetic acid methyl ester 
• 7664-93-9 sulfuric acid 
• 76854-15-4 C₂₀H₂₃NO₂ 
• 67-56-1 methanol 
• 200052-48-8 4-phenyl-piperidine-4-carboxylic acid 4-toluene sulfonate 
• 167262-47-7 1-tert-butyloxycarbonyl-4-phenyl-piperidine-4-carboxylic acid methyl ester 
• 24476-55-9 N-(p-tosyl)-4-phenyl-4-cyano-piperidine 

Downstream Products

• 166809-18-3 3-[4-methoxycarbonyl-4-phenyl piperidin-1-yl]propylamine 
• 1246390-30-6 1-[4-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzoyl]-4-phenyl-piperidine-4-carboxylic acid methyl ester 
• 3627-45-0 4-phenyl-piperidine-4-carboxylic acid 
• 103166-95-6 1-(3-cyano-3,3-diphenyl-propyl)-4-phenyl-piperidine-4-carboxylic acid methyl ester 
• 875831-88-2 C₁₃H₁₆N₂O₃ 
• 749913-39-1 4-phenyl-1-[5-(1-pyrrolidinylcarbonyl)-2-pyridinyl]-4-piperidinecarboxylic acid, methyl ester 
• 166808-36-2 5-[3-(4-methoxycarbonyl-4-phenyl-piperidin-1-yl)-propylcarbamoyl]-2,6-dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 2-cyano-ethyl ester 
• 166808-37-3 5-[3-(4-methoxycarbonyl-4-phenyl-piperidin-1-yl)-propylcarbamoyl]-2,6-dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 

Relevant articles and documents

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

The present application relates to compounds of formula (I) wherein the definitions are as described in claim 1. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Pa

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.